[Characteristics and management of ST-elevation myocardial infarction in France: Regional variations in 2010]

Ann Cardiol Angeiol (Paris). 2015 Dec;64(6):427-33. doi: 10.1016/j.ancard.2015.10.001. Epub 2015 Nov 5.
[Article in French]

Abstract

Data on regional variations in the characteristics, management and early outcome of patients admitted with ST-elevation myocardial infarction (STEMI) in France are limited. We used data from the FAST-MI 2010 registry to determine whether regional specificities existed, dividing the French territory into 6 larger geographical regions. Variations in the patients' characteristics were found, partly related to regional variations in demography. Acute reperfusion strategy showed more use of primary percutaneous coronary intervention in the greater Paris area, compared to other regions, which would be expected owing to geography and local availability of catheterization laboratories. Overall, however, in-hospital management showed more similarities than differences across regions. Complications, and in particular in-hospital mortality, did not differ significantly among regions.

Keywords: Infarctus avec sus-décalage; Management; Mortality; Mortalité; Prise en charge; Regional variations.; ST-elevation myocardial infarction; Variations régionales..

Publication types

  • Comparative Study
  • Multicenter Study

MeSH terms

  • Aged
  • Aged, 80 and over
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
  • Drug Therapy, Combination
  • Female
  • France / epidemiology
  • Heart Conduction System / physiopathology*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Male
  • Middle Aged
  • Myocardial Infarction / epidemiology*
  • Myocardial Infarction / mortality
  • Myocardial Infarction / physiopathology
  • Myocardial Infarction / therapy*
  • Myocardial Reperfusion / methods*
  • Percutaneous Coronary Intervention / methods
  • Prevalence
  • Risk Factors
  • Treatment Outcome

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors